Publications by authors named "N Horeweg"
Of the 4 molecular subtypes of endometrial cancer (EC), p53-abnormal (p53abn) EC is associated with abundant copy number alterations and the worst clinical outcome. Patients with p53abn EC have the highest risk of disease recurrence and death, independent of tumor grade and histologic subtype. Currently, all invasive p53abn ECs are considered high risk, and no prognostic biomarkers have yet been found that can aid in clinical management.
View Article and Find Full Text PDFBackground: This systematic review and meta-analysis aimed to investigate the survival outcomes following cytoreductive surgery (CRS) in patients with primary stage IV endometrial cancer (EC).
Methods: We systematically searched the Cochrane Library, Embase, MEDLINE/PubMed, and Web of Science for original studies reporting survival outcomes of primary stage IV EC after complete, optimal, and incomplete CRS. Pooled hazard ratios (HRs) for overall survival (OS) comparing optimal CRS with incomplete CRS were calculated using a random-effects model.
Article Synopsis
- Recent research on the HER2-targeted therapy trastuzumab-deruxtecan has led to a study examining HER2-low status in over 800 advanced endometrial cancer (EC) cases, which typically have a poor prognosis despite numerous treatment options.
- The study found that 17.2% of tumors were HER2-low, with higher frequencies in recurrent or metastatic EC (35.6%) and primary stage IV EC (29.9%), indicating HER2 status is present across various EC classifications without independent prognostic value.
- The findings suggest that a significant portion of high-risk and metastatic EC cases exhibit HER2 overexpression, emphasizing the importance of broad HER2 testing and potential treatment opportunities for diverse patient groups.
Purpose: BIOEMBRACE was designed to study the impact of biomarkers in addition to clinicopathological factors on disease outcomes in patients treated with chemoradiation and magnetic resonance imaging (MRI)-guided brachytherapy (BT) for locally advanced cervical cancer in the EMBRACE study.
Methods And Materials: Between 2018 and 2021, 8 EMBRACE-I sites contributed tumor tissue for the immunohistochemistry of p16, PD-L1, and L1CAM. These biomarkers and clinicopathological factors (International Federation of Gynecology and Obstetrics 2009 stage, nodal status, histology, and necrosis on MRI) were analyzed to predict poor response at BT (high-risk clinical target volume [HR-CTV] ≥ 40 cc) at BT) and 5-year local control, pelvic control, and disease-free survival.